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Abstract The enzyme alpha-methylacyl-coenzyme A race-
mase plays an important role in the beta-oxidation of
branched-chain fatty acid and its derivatives. It has been
used to detect prostatic adenocarcinoma and high-grade
intraepithelial neoplasia, and recently also as a marker for
other neoplasms, including those of the genitourinary sys-
tem, breast, upper and lower gastrointestinal tract and their
precursor lesions. We assessed expression of alpha-
methylacyl-coenzyme A racemase by immunohistochemis-
try in neuroendocrine tumours of the stomach to determine
differences in the incidence and pattern of expression among
different types of gastric neuroendocrine tumours. While
none of the grade 1 neuroendocrine tumours were immuno-
reactive, 67 % of grade 2 neuroendocrine tumours and 90 %
of neuroendocrine carcinomas were positive for alpha-
methylacyl-coenzyme A racemase. Furthermore, an adeno-
carcinoma component was found in 72.5 % (37 of 51) of
neuroendocrine carcinomas, whereas none of the grade 1
and 2 neuroendocrine tumours contained an adenocarcino-
ma component. In 83 % of neuroendocrine carcinomas, the
adenocarcinoma component was positive for alpha-
methylacyl-coenzyme A racemase, and both adenocarcino-
ma and neuroendocrine carcinoma components stained pos-
itively in 78 % of these cases. Our results indicate that
alpha-methylacyl-coenzyme A racemase is a useful marker
for distinguishing between grade 1 (negative) and grade 2
neuroendocrine tumours, and neuroendocrine carcinoma of
the stomach (frequently positive). Different patterns of
alpha-methylacyl-coenzyme A racemase expression be-
tween gastric neuroendocrine tumours and neuroendocrine
carcinoma suggest that these might develop via different
tumourigenic pathways.
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Introduction
Neuroendocrine neoplasms generally show characteristic
histological features, such as trabecular, sheet-like and
solid alveolar architecture, and neuroendocrine granules
in the cytoplasm of tumour cells, which sometimes
contain hormonal products. According to the latest
World Health Organization (WHO) classification of di-
gestive system tumours (fourth edition, 2010), gastric
neuroendocrine neoplasms are divided into neuroendo-
crine tumour (NET) and carcinoma (NEC), and the
former is further divided into grade 1 NET (NET G1)
and grade 2 NET (NET G2). This classification is based
on the proliferative activity of tumour cells. NET G1,
NET G2 and NEC of the stomach correspond to what
was formerly called carcinoid tumour (synonymous with
well-differentiated endocrine tumour), atypical carcinoid
tumour and endocrine cell carcinoma (synonymous with
small cell carcinoma), respectively. Gastric NET G1 is
usually composed of uniform small cells with little
atypia, limited growth within the submucosa and rare
angioinvasion or distal metastasis, corresponding clini-
cally with low-grade malignant potential and favourable
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prognosis. NET G2 is also known as a malignant car-
cinoid and sometimes demonstrates aggressive biological
behaviour [1]. NEC is predominantly composed of atyp-
ical cells, larger than those of NET with conspicuous
mitotic figures, and demonstrates aggressive biological
behaviour with frequent angioinvasion, distant metasta-
sis and poor prognosis. Ki67 and p53 are reported to be
helpful markers to distinguish between neuroendocrine
cell neoplasms, but the histopathological distinction be-
tween NET G1 and NET G2, or between NET G2 and
NEC [2], remains difficult.
Alpha-methylacyl-coenzyme A racemase (AMACR)
is an enzyme that plays an important role in the beta-
oxidation of branched-chain fatty acids and their deriv-
atives [3–5]. AMACR was originally identified in mito-
chondria and peroxisomes of rat liver cells. Given the
involvement of AMACR in the metabolism of lipids, it
was speculated that overexpression of this protein might
lead to alterations in the balance of cellular oxidants,
which in turn might contribute to the pathogenesis of
neoplasms. AMACR has been primarily used to detect
prostatic adenocarcinoma and high-grade intraepithelial
neoplasia [6, 7], and recently also as a differential and
prognostic marker of several other neoplasms and their
precursor lesions, including those from the prostate,
genitourinary system, breast and upper and lower GI
tract [7–21].
As yet, only two reports have considered AMACR ex-
pression in neuroendocrine neoplasms [17, 22], and only
five reports mention AMACR expression in gastric neo-
plasms [18–21, 23]. These studies found that AMACR
expression distinguishes between adenoma and/or ordinary
adenocarcinoma and non-neoplastic conditions, and that
AMACR expression may depend on tumour differentiation.
However, none of these studies mention gastric NET or
NEC. The aim of our study was to clarify the differences
in the incidence and patterns of immunohistochemically
determined expression of AMACR between NET G1,
NET G2 and NEC of the stomach.
Materials and methods
Case selection
For the present study, 82 cases of gastric neuroendocrine
neoplasms, registered between 1985 and 2011 at the Divi-
sion of Molecular and Functional Pathology, Niigata Uni-
versity Graduate School of Medical and Dental Sciences,
Niigata City, Japan, were selected. The tumours came from
1 Russian and 80 Japanese patients, who had undergone
endoscopic resection or surgical resection without systemic
adjuvant therapy. All samples had been fixed in 10 % for-
malin solution and embedded in paraffin. Clinical informa-
tion was obtained from the medical records of each patient.
Endocrine differentiation of tumour cells was confirmed by
diffuse and intense immunoreactivity of at least one of well-
known endocrine markers, including chromogranin A, synap-
tophysin and neural cell adhesion molecule (NCAM, CD56).
The neuroendocrine cell neoplasms were divided into
three groups according to the 2010 WHO classification
[1]: (1) NET G1 (22 cases), with a mitotic count of less
than two per ten high-power fields (HPF) and/or a Ki67
index ≤2 %; (2) NET G2 (9 cases), with a mitotic count of
2–20 per ten HPF and/or a Ki67 index of 3–20 %; and (3)
NEC (51 cases), with a mitotic count >20 per ten HPF and/
or a Ki67 index >20 %. The study was approved by the
ethics committee of Niigata University Graduate School of
Medical and Dental Sciences.
Histological diagnosis
The diagnosis of gastric neuroendocrine neoplasms was
confirmed by two pathologists (AA and KN), who reviewed
the clinical information and histological slides. The histo-
logical analysis recorded the following: depth of tumour
invasion, lymphatic invasion, angioinvasion, mitotic fre-
quency and lymph node metastasis. Lymphatic invasion
and angioinvasion were confirmed via immunostaining for
D2-40 and CD34.
Fig. 1 Intensity of AMACR immunohistochemical staining; weak (a), intermediate (b) and strong (c)
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Immunohistochemistry
The most invasive area of each tumour was selected, and the
corresponding paraffin block was cut into consecutive 3-μm
sections for immunostaining, after a representative haema-
toxylin and eosin (H&E) section was stained.
Immunohistochemical analysis was performed via the
high polymer method, using the Histofine MAX-PO
(MULTI) kit (Nichirei Biosciences Inc., Tokyo, Japan).
Sections were deparaffinized and rehydrated, then micro-
waved at 98 °C for seven cycles of 3 min (i.e. for synapto-
physin, CD34, D2-40, and AMACR) or autoclaved at 121 °C
for 20 min (i.e. for Ki-67, chromogranin A, NCAM and
p53) in 10 mmol/L of citrate buffer (pH 6.0, for all anti-
bodies except AMACR) or 1 mmol/L Tris–EDTA buffer
(pH 9.0, for AMACR) to retrieve antigenic activity. Endog-
enous peroxidase activity was blocked by 0.3 % hydrogen
peroxide in methanol for 20 min. In all sections, except Ki-
67, non-specific binding was blocked with 10 % normal
serum. Sections were incubated overnight with the follow-
ing primary antibodies: mouse monoclonal antibodies
against chromogranin A (DAK-A3, dilution at 1:500, Dako,
Glostrup, Denmark), NCAM (1B6, 1:100, Novocastra,
Newcastle, UK), CD34 (QBEnd-10, 1:200, Dako), D2-40
(D2-40, 1:200, Signet Laboratories, Dedham, MA, USA),
p53 (PAb1801, 1:40, Novocastra) and Ki67 (MIB-1, 1:200,
Dako), as well as rabbit monoclonal antibodies against
synaptophysin (1:100, Dako) and AMACR (p504s, clone
13H4, 1:100, Dako). Sections were then incubated with
Histofine Simple Stain MAX-PO (MULTI) (Nichirei Bio-
sciences Inc.) for 30 min at room temperature. Antibody–
antigen reactivity was visualized with diaminobenzidine,
and sections were lightly counterstained with haematoxylin.
Finally, the sections were dehydrated with graded ethanol
and xylene and mounted with coverslips.
Interpretation of AMACR immunohistochemical expression
Sections from ten cases of prostate cancer served as
positive control for AMACR, whereas sections incubat-
ed with non-immune mouse IgG served as negative
controls. AMACR expression was considered positive
when the cytoplasm of >5 % of tumour cells was
stained. Positive AMACR staining was divided into
Fig. 2 Immunoexpression of
AMACR in adenoNEC case.
The adenocarcinoma part and
NEC part showed histologic
continuity (a) and similar strong
immunoexpression pattern of
AMACR (b)
Table 1 Clinicopathological features of neuroendocrine neoplasms of the stomach







Sex, male/female 12:10 7:2 40:11 NS NS NS
Age (years), average±standard
deviation
57.6±11.7 56.8±15.0 69.6±9.8 NS 0.001 0.01
Tumour size (mm), median
(quartile range)
6 (4–10) 20 (8–30) 48.5 (30–61) NS <0.001 0.002
mp invasion 0/22 (0 %) 4/9 (44 %) 39/51 (76 %) 0.005 <0.001 NS
Mitosis (per ten HPF), mean
(range)
0 (0–1) 2 (1–4) 25 (15–43) <0.001 <0.001 <0.001
Lymphatic invasion 0/22 (0 %) 6/9 (67 %) 47/51 (92 %) <0.001 <0.001 NS
Angioinvasion 0/22 (0 %) 4/9 (44 %) 39/51 (76 %) 0.005 <0.001 NS
LN metastasis 0/9 (0 %) 3/5 (60 %) 33/48 (69 %) NS <0.001 NS
NET neuroendocrine tumour, NEC neuroendocrine carcinoma, NS not significant, mp muscularis propria, HPF high-power field, LN lymph node
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three patterns: strong (intense and granular cytoplasmic stain),
weak (faint and diffuse cytoplasmic stain) and intermediate
(mixture of strong and weak patterns) (Fig. 1).
Interpretation of Ki67 index and p53 immunohistochemical
expression
The Ki67 index was determined via MIB-1 antibody
staining and was expressed as a percentage of 1,000
tumour cells counted in areas with strongest nuclear
labelling (“hot spots”). Expression of p53 protein was
classified as follows: (−) negative, (+) scattered positive
cells, (++) focal aggregates of positive cells and (+++)
positive cells occurring in most tumour cells. The stain-
ing patterns (++) and (+++) were considered as over-
expression of p53 protein, consistent with our previous
report [2].
Statistical analysis
Differences between groups were determined via Fisher's
exact and χ2 tests. All statistical analyses were conducted
with PASW statistics 17.0 (SPSS Japan Inc. Tokyo, Japan).
A p<0.05 was considered statistically significant.
Results
Clinicopathological features
The clinicopathological features of the studied endocrine
neoplasms of the stomach are summarized in Table 1. The
three types of gastric neuroendocrine neoplasm demonstrat-
ed significant differences in tumour size, invasion into the
muscular layer or deeper, mitosis, lymphatic invasion,
angioinvasion and lymph node metastasis.
Fig. 3 Immunohistochemical
staining of NEC and NET G2.
NEC (a, H&E) demonstrates
strong immunoexpression of




Table 2 AMACR expression in




Type of tumour Number AMACR expression p value
Weak Intermediate Strong Total
NET G1 22 0 0 0 0 <0.001
NET G2 9 3 (33.3 %) 1 (11.1 %) 2 (22.2 %) 6 (66.7 %)
NEC 51 7 (13.7 %) 16 (31.4 %) 23 (45.1 %) 46 (90.2 %)
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Histological features
An adenocarcinoma component was associated with 37 of
51 (73 %) NEC cases (adenoNEC), and 12 of 37 (32.4 %)
cases were diagnosed as mixed adenoneuroendocrine carci-
noma (MANEC), a special type of adenoNEC with either
component of adenocarcinoma and NEC exceeding 30 %
according to the current WHO classification [1]. The
remaining 14 cases demonstrated NEC without any signs
of adenocarcinoma. Specifically, the adenocarcinoma com-
ponent that was associated with NEC was limited to the
mucosa (68 %, 25 of 37) or submucosa (32 %, 12 of 37),
and 34 of 37 cases (92 %) were of well to moderately
differentiated adenocarcinoma. Furthermore, 89 % of the
differentiated adenocarcinoma components were histologi-
cally continuous with NEC components in the submucosal
layer (Fig. 2). Conversely, no NET G1 or G2 cases contained
an adenocarcinoma component (0 of 22 and 0 of 9).
AMACR expression in the non-neoplastic epithelium
AMACR was not expressed in the non-neoplastic gastric
mucosa surrounding each tumour. Intestinal metaplasia was
weakly positive for AMACR staining in <5 % of cells of the
9 % of cases that were considered negative.
AMACR expression in NET G1, NET G2 and NEC
AMACR expression levels in gastric neuroendocrine tumours
are summarized in Table 2. While none of the NET G1 cases
expressed AMACR (0 of 22), 67 % (six of nine) of NET G2
cases expressed AMACR. Specifically, there was strong
staining in 33 % (two of six), intermediate staining in 17 %
(one of six) and weak staining in 50 % (three of six) of NET
G2 (Fig. 3). Furthermore, AMACR was expressed in 90 %
(46 of 51) of NEC cases, where 50% (23 of 46) showed strong
staining, 35 % (15 of 46) showed intermediate staining and
15 % (7 of 46) weak staining. Of the NEC cases associated
with adenocarcinoma (adenoNEC), the adenocarcinoma
component expressed AMACR in 84 % (31 of 37) and the
NEC in 89 % (33 of 37). In adenoNEC cases, there was
no significant difference in AMACR expression between
MANEC and non-MANEC (91.6 vs 80.0 %). Interestingly,
93 % (13 of 14) of NEC without an adenocarcinoma compo-
nent was positive for AMACR. The adenocarcinoma and
NEC components were both positive in 78 % (29 of 37) of
cases (Fig. 2). The AMACR expression status was concordant
between the adenocarcinoma and NEC component in 83.8 %
(31 of 37) of cases, both positive in 78 % (29 of 37) and both
negative in 5.5 % (2 of 37) (Fig. 2). For adenoNEC cases,
AMACR staining was concordant between the adenocarci-
noma and NEC components in 52 % (15 of 29), and the
staining patterns were similar (i.e. strong–intermediate,
intermediate–weak) in 86 % (25 of 29) of cases. AMACR
staining was strong for both adenocarcinoma (15 of 31,
48 %) and NEC (23 of 46, 50 %) (Fig. 2). There were no
significant differences between the AMACR-positive and
AMACR-negative NEC, and NET G2 cases with respect to
clinical features, including tumour size, depth of invasion,
lymphatic invasion, angioinvasion and lymph node metasta-
sis (Table 3).
Correlations between Ki67-index, p53 expression
and AMACR expression
Expression of p53 and Ki67 index are presented in Table 4.
Overexpression of p53 and AMACR expression correlated
in neuroendocrine tumours of the stomach. In NET G1
cases, both p53 and AMACR were negative. In NEC cases,
p53 overexpression (67 %) and AMACR expression (90 %)
Table 4 Correlation between Ki67 index, p53 overexpression and AMACR positivity in neuroendocrine neoplasms of the stomach
Type of tumour Ki67 index, mean (range) p53 overexpression (n) AMACR positivity (n)
NET G1 1.7 % (1.5–2) 0 (0/22) 0 (0/22)
NET G2 7.2 % (4.5–10) 0 (0/9) 66.7 % (6/9)
NEC 67.1 % (55.4–78.9) 66.7 % (34/51) 90.2 % (46/51)
NET neuroendocrine tumour, NEC neuroendocrine carcinoma
Table 3 Relationship between
the AMACR-positive and





AMACR positive AMACR negative
Tumour size (mm), median (quartile range) 49 (18–61) 57 (20–60)
mp invasion 35/46 (76 %) 4/5 (80 %)
Lymphatic invasion 43/46 (93 %) 4/5 (80 %)
Angioinvasion 35/46 (76 %) 4/5 (80 %)
LN metastasis 30/43 (70 %) 3/5 (60 %)
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often concurred (67 %). However, in NET G2 cases without
overexpression of p53, 67 % (six of nine) of cases expressed
AMACR. The Ki67 showed a linear correlation with
AMACR expression in NET G1, NET G2 and NEC.
Discussion
Although AMACR is expressed in numerous tumour types,
its expression has never been studied in neuroendocrine
neoplasms of the digestive system. There are only two
papers showing significant AMACR expression in neuroen-
docrine neoplasms of the lung. In the present study, the
incidence and pattern of immunohistochemical expression
of AMACR in NET G1, NET G2 and NEC of the stomach
were investigated.
AMACR overexpression has been observed in prostate
and colorectal carcinomas, and linked to a high-fat diet [13].
However, the exact mechanism by which a high-fat diet
might contribute to tumourigenesis in these organs remains
unclear. Furthermore, AMACR expression may not be lim-
ited to tumours linked to dietary factors and may be in-
volved in carcinogenesis via a degradation pathway of
branched-chain fatty acids, or an epiphenomenon. The path-
ologenetic link between dietary branched-chain fatty acids
and cancer has not yet been determined, and it remains
unclear why branched-chain fatty acids appear to be more
carcinogenic than straight-chain fatty acids. Some investi-
gators have speculated that the overexpression of AMACR
may lead to alteration in the balance of cellular oxidants,
resulting in the production of reactive oxygen species,
which leads to oxidative stress, and then DNA damage [24].
In the present study, we found that AMACR expression
was significantly higher in NEC (90 %) and NET G2 (67 %)
than in NET G1 (0 %), and that AMACR expression corre-
lated with the Ki67 index (Table 4). These findings suggest
that AMACR might be a good marker for differentiating
between these neoplasms. Overexpression of p53 has been
considered to be the best marker to distinguish between
NEC and NET. Indeed, 67 % of our NEC but no NET cases
overexpressed p53. Furthermore, AMACR was more often
positive than p53 (90 vs 67 %) in NEC, and furthermore,
AMACR was expressed in 67 % of NET G2, suggesting that
AMACR may better discriminate between grade 1 and 2
gastric neuroendocrine neoplasms (i.e. not only between
NEC and NET, but also between NET G1 and NET G2).
Only a few studies have been performed regarding the
prognostic significance of AMACR expression in gastric
tumours, and it is still controversial [18–20]. We did not
find a correlation between aggressive features, such as lym-
phatic invasion or lymph node metastasis, and AMACR
expression in NET G2 and NEC. This may be due to the
small number of samples, and future study with a higher
number of cases, especially of NET G2, might clarify this
issue.
Many gastric NET cases are formed by aggregation of
endocrine cell micronests, predominantly composed of
enterochromaffin-like cells, and caused by the trophic effect
of hypergastrinemia, which occurs upon extensive atrophy
of the fundic gland mucosa [25]. Patterns of AMACR ex-
pression concurred between adenocarcinoma and NEC com-
ponents of adenoNEC. The absence of an adenocarcinoma
component in NET G1 and G2 cases might suggest not only
the histological features, but also the tumourigenic pathway
between NET and NEC are different. The possibility that
NEC originates from a preceding adenocarcinoma compo-
nent might be considered.
Shilo et al. reported overexpression of AMACR in pul-
monary neuroendocrine tumours, with AMACR expression
in 72 % (31 of 43) of typical carcinoids, 52 % (15 of 29) of
atypical carcinoids, 70 % (16 of 23) of large cell neuroen-
docrine carcinomas and 51 % (32 of 63) of small cell
carcinomas [22]. Jiang et al. reported that pulmonary small
cell carcinomas (zero of five) and pulmonary carcinoid
tumours (zero of ten) are negative for AMACR [17]. These
data suggest that the malignant potential of pulmonary car-
cinoids is different from that of gastric carcinoids, as
reflected in AMACR staining.
One important limitation of our study is that we used a
small number of specimens, especially of NET G2, and
therefore, additional studies are necessary to further clarify
the overexpression of AMACR in the development of NEC
and NET G2, as well as the use of AMACR in differentiat-
ing between various neuroendocrine neoplasms of the
stomach.
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